The Antisynthetase Syndrome by Jan Tore Gran & Øyvind Molberg
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
The Antisynthetase Syndrome 
Jan Tore Gran and Øyvind Molberg 
Department of Rheumatology, Oslo University Hospital,  
Rikshospitalet, Oslo,  
Norway  
1. Introduction 
The antisynthetase syndrome (ASS) was first described by Marguerie and coworkers in 1990 
as a triad of polymyositis, diffuse interstitial lung disease (ILD) and serum autoantibodies to 
aminoacyl transfer RNA synthetases (anti-ARS) (1). Later, cohort studies have indicated that 
20-25 % of patients diagnosed with polymyositis (PM) or dermatomyositis (DM) have anti-
ARS antibodies (2-4). In most cases, these anti-ARS+ PM/DM patients also have ILD. The 
ILD is, in fact, the major determinant of morbidity and mortality in the ASS.  
The most common of the anti-ARS, anti-Jo-1, was first described in 1980. Three years later, 
the Jo-1 antigen was identified as histidyl-tRNA synthetase (5;6). In recent case series, the 
anti-Jo-1 antibody accounts for 68-87% of the anti-ARS observed in ASS (7-9). The seven 
other anti-ARS identified (Table 1) are all rare, but their relative frequencies have not been 
extensively studied (7;8). With very few exceptions, each patient has only one anti-ARS 
antibody (10). More than half of the anti-ARS+ patients also possess anti-SSA autoantibodies 
(8;9;11) and then most frequently anti-Ro52 (11). 
2. Disease definition  
At present, there is no internationally accepted definition of ASS and no classification 
criteria have been established. Consequently, the clinical characteristics of published ASS 
cases vary substantially. Some studies have included all patients with anti-ARS, regardless 
of clinical manifestations, while others have selected patients according to predefined 
clinical features.  
As it is generally agreed upon that ILD is the clinical hallmark of ASS, this clinical feature is 
regarded mandatory for the diagnosis of ASS by most workers. The finding of ILD in 64-100 
% of patients possessing anti-Jo-1 autoantibodies underlines the close association between 
anti-ARS and ILD (3;9;12-17). In one study (3), anti-ARS were found in 3% of DM without 
ILD as opposed to 63% in DM with ILD, further emphazising the importance of pulmonary 
disease in ASS. Thus, ILD is an important but not a compulsory feature of ASS diagnosis. 
In ASS, the extent and severity of myopathy may vary considerably (18). Usually, the 
myositis is less severe than in DM and PM without anti-ARS. Some cases develop clinically 
overt myositis, others present with hypomyopathic or even amyopathic disease. Thus, a 
diagnosis of ASS should be considered even in the absence of myositis.  
Criteria for the ASS have been proposed recently (19). These criteria suggest that a diagnosis 
of ASS could be made in the presence of positive serologic testing for an anti-ARS plus one 
www.intechopen.com
 
Idiopathic Inflammatory Myopathies – Recent Developments 
 
66
of the following; myositis, ILD, arthritis, fever, Raynaud`s phenomenon or Mechanic`s 
hands. We feel, however, that ILD and myositis represent the most important clinical 
features of ASS, hence at least one of them should be included in such classification criteria. 
It is thus tentatively suggested that a diagnosis of definite ASS should require anti-ARS and 
either ILD and/or inflammatory myopathy plus at least one other clinical criterion 
commonly found in this syndrome (Table 2). A diagnosis of probable ASS would be met 
when either ILD and/or inflammatory is present in a patient with anti-ARS.  
3. Epidemiology  
ASS is a rare disease, but its frequency in the general population is not known. In most 
studies, the estimated population prevalence of PM/DM is around 15/100 000 (refs). If 25% 
of the PM/DM patients have anti-ARS, then the prevalence of the anti-ARS should be least 
3-4/100 000. ASS has been reported in both Caucasian, Asian and Afro-American patients, 
but it is known if the prevalence of the disease differs between ethnic groups.  
The age at onset among adults ranges from 19 to 82 years with a mean age at onset varying 
from 43 to 60 yrs (2;3;9;12;20). Very few children and adolescents with ASS have been 
reported. A female dominance, with about twice as many females as men affected, has been 
found in most series (3;9;12).  
4. Pathology 
Muscle. The results of histological examination of muscle tissue are somewhat conflicting. 
In one early study (21), the authors demonstrated prominent perimysial inflammation with 
fragmentation and perifascicular myopathic changes whereas endomysial inflammation was 
uncommon. Consequently, these findings suggested a dermatomyositis pattern in ASS 
rather than polymyositis. In subsequent reports, the picture has become less clear as a 
polymyositis pattern has been more commonly observed than a dermatomyositis pattern 
(13;22). Some studies have, however, concluded with similar frequencies of polymyositis 
and dermatomyositis in ASS (8;23). In our own experience, the majority of cases exhibit 
changes compatible with a diagnosis of dermatomyositis. The frequent occurrence of 
dermatological lesions to some extent supports a closer relationship to dermatomyositis 
than to polymyositis. Moreover, the frequent findings of vasculopathic changes at nail fold 
capillaroscopy may also favor a vasculopathic genesis rather than a myopathic one. Further 
studies of muscle and vessel pathology in ASS are clearly warranted. 
Lung. Limited pathologic case series have shown that the ILD in ASS encompasses various 
histologic subtypes and both non-specific interstitial pneumonia (NSIP), usual interstitial 
pneumonia (UIP), cryptogenic organizing pneumonia (COP) and diffuse alveolar damage 
(DAD) may be diagnosed (20;24;25). 
5. Genetics 
Most works on the genetics of ASS have been confined to candidate genes in the very 
polymorphic Human Leukocyte Antigen (HLA) region. All the published studies confirm 
that the HLA-DRB1*0301, DQA1*0501 and DQB1*0201genes are risk factors for the 
development of anti-Jo-1+ ASS (7).  
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6. Disease mechanisms 
Already in the 1980’s it was speculated that the in vivo formation of anti-histidyl tRNA 
synthetase antibodies was driven by viral infections, possibly through molecular mimicry 
between viral proteins and histidyl tRNA synthetase (HRS) (26). The basic idea was that the 
cross-reactive anti-HRS (anti-Jo-1) caused damage through its ability to inhibit HRS and/or 
through formation of immune complexes . Although never backed by experimental 
evidence, the viral hypothesis is still highlighted in many reviews on ASS.  
More recent studies have focused more on auto-antigenic properties of the HRS molecule 
per se. A very interesting finding in this respect, was that soluble HRS acted as a chemokine 
and attracted CD4+ T cells (27). In inflamed tissues marked by cell destruction and high 
concentrations of free HRS this mechanism could contribute to the breaking of tolerance 
(27). Another observation has been that HRS expression is upregulated in regenerating 
muscle cells. Areas with active myositis should thus have very high expression of HRS. 
Together, these studies indicate that muscle inflammation per se may increase the levels of 
HRS and the likelihood of initiating immune responses to HRS, at least in genetically 
susceptible individuals. Whether similar mechanisms are operative in the lung is not 
known, but it has been suggested that HRS adopts a more immunogenic conformation in 
the lung than in blood cells (28). Previously, it was shown that T cells from the blood of both 
ASS patients and healthy individuals often recognized HRS (29). No data on T cell or B cell 
reactivities to HRS in inflamed muscle or lung exist, but CD4+ T cells from the 
bronchoalveolar lavage fluid of two anti-Jo-1+ ASS patients have been shown to contain the 
same T cell receptor gene family (30). 
7. Clinical features 
Disease onset. At onset of disease, respiratory symptoms are present in 40-60 % of patients. 
In one case series (3), the onset of ILD preceded the onset of myositis in 33%, while myositis 
and ILD developed simultaneously in 60%. Myositis preceding ILD was observed in only 
7% of the patients. At onset of disease, patients may also present with constitutional 
symptoms such as fever (seen in 35-90% of the patients), loss of appetite and weight loss 
(2;3;31;32). Other features seen at onset of ASS are joint pain, arthritis, tenosynovitis, and 
Raynaud`s phenomenon.  
Respiratory symptoms. The reported frequency of ILD in ASS varies, depending on patient 
selection and the sensitivity of the tests applied to detect ILD (18). Most reports indicate that 
the frequency of ILD in the ASS is in the range of 70-95 % (3;9;12-14;16;31), but some few 
case series have found lower frequencies (2;33). The frequency of ILD appears to be highest 
among ASS patients who are anti-PL12 positive, as ILD was diagnosed in 90-100% of PL-12 
positives as compared to 50-75% in Jo-1 positives (20;34). 
Most frequently, patients complain of shortness of breath and cough. The lung disease may 
present very acute, subacute or asymptomatic ILD with development of clinically apparent 
ILD later on. Consequently, the type of onset may be classified into three groups, type I 
acute, type II gradual and type III asymptomatic. Such a classification may be important for 
predicting outcome and selecting optimal treatment.  
Muscle weakness is reported at onset of disease in 20-50 % of patients. Most commonly, it 
involves the proximal and axial muscles (31;33). Patients may also report muscular stiffness 
and pain. The muscular component is thus indistinguishable from that seen in PM and DM. 
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However, muscle involvement is less frequent and usually milder than in non-ASS patients 
(18). The reported accumulated incidence of myositis ranges from 40-94% (3).  
The tendency to milder myositis among cases with PL-12 was further supported by the 
findings of a frequency of 60% PL-12 among patients without clinically evident myositis 
(35). ASS may also present with a hypo- or even amyopathic dermatomyositis pattern. 
Skin symptoms. Dermatological features are frequently encountered in ASS, being 
observed in 7-70% of the various reports (3;9;12;14;32;33). Mechanic`s hands appear as 
fissuring and scaling of the lateral and distal aspects of the hand, and is rarely seen in 
conditions other than ASS. In ASS, this clinical feature is seen in 0-32% of cases (3;9;12;31-
33). Histological examinations of biopsy specimens of Mechanic`s hands have displayed 
mononuclear cell infiltrates around the blood vessels and mucin deposition in the dermis 
(36). As in DM, heliotrophic rash is seen in 7-38% (3;14;31;36). Gottron`s lesions appearing 
on bony prominences such as finger knockles are observed in 9-69% of patients (3;31;33;36). 
Microvascular changes presenting as periungual erythema may also be seen (1). Although 
infrequently reported, V-sign and Shawl-sign may also develop in ASS. 
Joint pain or swelling. Arthritis is a frequent clinical manifestation of ASS, being seen in 42-
82% of reported cases (2;3;9;12;14;36). Although rare, a subluxating arthropathy involving 
the distal joints of the fingers (37) is a rather characteristic feature of ASS. ASS may also 
present as a symmetric inflammatory polyarthritis initially indistinguishable from that of 
rheumatoid arthritis (38). Tenosynovitis has also been reported. Joint pain without signs of 
inflammation also occur frequently in ASS (66-89%) (2;32). 
Gastrointestinal symptoms. Involvement of the gastrointestinal canal is usually restricted to 
the distal parts of the oesophagus. The incidence of distal oesophageal dysmotility evidently 
depends on the tests used to identify the abnormality, but is diagnosed in 5-52% of the 
reports (9;12;31-33). Oesophageal disease is an important clinical feature of ASS as 
dysphagia leading to aspiration may further damage the already compromised pulmonal 
function. In patients with end stage interstitial lung disease, this manifestation may restrict 
patients`possibilitis of being accepted for lung transplantation. Routine examinations using 
barium enema x-ray is therefore recommended to diagnose oesophageal dysmotility which 
should be treated vigorously. 
Vascular symptoms. Clinical signs of vasculopathy may appear. Raynaud`s phenomenon 
accompanies ASS in 30-50 % of cases (2;3;9;12;14;20;32). Skin necrosis and ischemic ulcera 
have also been observed in ASS (39). Pulmonary arterial hypertension has not been 
subjected to studies aimed at detecting its true incidence that is using echocardiography to 
screen all cases. It is, however, infrequently observed in DM and PM, and in one study (43) 
PAH was diagnosed by echocardiography in 16 of 198 consecutive cases (0,8%). It was thus 
concluded that mild to severe PAH is a rare complication of IIM (43). In ASS, cases with 
fatal (40) and acute (41-43) PAH have been observed. In our patient cohort of 67 cases of 
ASS, PAH diagnosed by right heart catherization was observed in nine cases and 
represented a frequent cause of death in this syndrome.  
Other clinical features seen rather commonly in ASS include, sicca symptoms (8-54%) 
(2;9;31;32), sclerodactyli (12) and subcutaneous calcinosis (44). Glomerulonephritis may be 
seen (45).  
Clinical features stratified by anti-aaRS. In general, the similarities of the clinical features 
among patients possessing different ASS are rather impressive. Some differences have, 
however, been suggested. Due to low numbers of non-Jo-1 positive ASS patients reported, it 
is prudent that these differences are considered preliminary and interpreted cautiously. 
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Among PL-12 positive ASS, the histological features of ILD is predominantly of the NSIP 
pattern (20), while myositis is mostly mild (34). In one study (20), CK levels increased to up 
to twice the normal level in only two individuals. Interestingly, two of these cases were 
diagnosed with PAH.  
Patients with anti-PL7 autoantibodies may also show different clinical features when 
compared to Jo-1 positives. Anti-PL-7 autoantibodies have been associated with milder 
muscle weakness (46) and almost all patients reported have had ILD (46;47). Seven patients 
with anti-OJ autoantibodies were described by Sato et al (48) of whom all had ILD, and four 
presented muscle weakness and polyarthritis. None had Raynaud`s phenomenon or 
sclerodactyli. In a study of eight patients with anti-KS autoantibodies, 88% had ILD 25% 
(49). 
Other clinical associations. Anti-SSA antibodies, anti-Ro52 in particular, occur in more than 
50% of ASS (8;11) and have been associated with more severe lung fibrosis (13). In one study 
(50) patients without anti SSA autoantibodies more often lacked fibrosis on the initial CT 
scans compared to patients possessing these autoantibodies. In another study (33), patients 
with such autoantibodies seemed to be predisposed to the development of a more severe 
ILD as assessed by both HRCT and lung function tests. 
8. Disease associations 
Cancer. The increased risk of cancer in DM is well documented. In one study of 103 patients 
with DM, 15 patients had concomitant malignancy (51) and the risk of cancer was highest 
among those without myositis-specific autoantibodies. Thus, ASS was suspected to provide 
some protection against the development of cancer. However, subsequent case reports of 
concurrent ASS and cancer appeared (52;53), clearly showing that ASS does not provide 
total protection against development of malignant disease. Whether or not the risk of cancer 
is less in ASS compared to other IIM remains to be studied. However, in a recent study from 
Japan , 4.8 % of patients with DM and concomitant cancer possessed anti-Jo-1 antibody as 
opposed to 15.9 % in DM patients without malignant disease (54). Although these findings 
may indicate some protective effect of anti-ARS against development of malignancy, further 
studies are warranted to corroborate such an association. 
Other immune-mediated disorders. Approximately 5-8 % of anti-ARS cases manifest as 
overlap syndromes with another connective tissue disease such as systemic lupus 
erythematosus, systemic sclerosis and Sjøgren`s syndrome (55).  
9. Evaluation and diagnosis 
Assessment of the respiratory system. The diagnosis of ASS associated ILD is based on 
HRCT of lungs. Ground glass opacities, subpleural fibrosis and bronchiectasies, all due to 
compromise of the alveolar-capillary interface, may be observed early in the disease course. 
In some cases, the progression of ILD is severe, culminating in end stage pulmonal disease 
(honeycombing) after a rather short disease duration. In other cases, more limited 
abnormalities on HRCT are seen with little impact on lung function.  
 Lung function tests typically reveals a restrictive pattern with FVC or total lung capacity 
less than 80% of the predicted value for age and height and a decrease in the diffusing 
capacity for carbon monoxide. As lung function tests are readily reproducible and 
minimally invasive, such tests are recommended both for uncovering occult ILD and for 
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monitoring disease severity and disease progression. Lung biopsy offers unclear prognostic 
value (19), and is not recommended as a routine procedure in the evaluation of ASS.  
Assessment of the musculoskeletal system. Evaluation of muscular involvement reveals in 
the majority of cases significant elevations of creatin kinase (CK). Compared to PM, the 
elevations of CK are often modest, in the majority of cases not exceeding 5000 IU/ml (2;3;9). 
In a few cases, however, the myositis is severe, exhibiting CK levels of several thousands 
and causing severe muscular weakness. MRI will in cases of clinically overt disease show 
oedema initially, and by time development of fibrosis, fatty deposits and atrophy. In 
hypomyopathic patients, MRI and CK levels may be normal in spite of muscular weakness. 
In other cases of hypomyopathic ASS, there are no muscle complaints while CK levels may 
be elevated or MRI may show signs of inflammation. Amyopathic ASS denotes a condition 
in which neither clinical symptoms nor laboratory abnormalities are present.  
10. Assessment of other organ systems 
Further evaluation of patients with ASS should include barium oesophageal x-ray which in 
more than 25 % of cases will reveal distal oesophageal dysmotility. Diagnosis and proper 
treatment of oesophageal dysmotility is important to avoid further damage to the lungs by 
aspiration. Another important disease complication is represented by pulmonary 
hypertension, either pre- or post capillary. Echocardiography should therefore be 
considered in the work-up of ASS. If PAH is suggested by echocardiography, the diagnosis 
should be verified by right heart catherization. Capillaroscopy may show reduced capillary 
density (56), and in two studies nailfold capillary changes were detected in 31 and 89%, 
respectively (3;9). Whether or not the occurrence of such vasculopathic changes differ 
between those with a histologic pattern of dematomyositis as oppsoded to polymyositis 
remains to be studied. 
11. Evaluation of disease activity and disease severity 
Biomarkers for disease activity and disease severity have been incompletely studied in ASS. 
Whether or not traditional markers for acute phase responses such as SR and CRP correlate 
with the actual activity and progression of disease remains to be seen. In the initial phases of 
disease, an acute phase response may be evident. One study suggested that levels of  
anti-Jo-1 autoantibodies correlated with disease activity (12), but these findings await 
confirmation. Thus, further research of ASS biomarkers for disease activity and disease 
severity should be strongly encouraged. 
12. Treatment 
Treatment of ASS is a challenge as no controlled trials have been performed and 
recommendations are based on single case reports and small patient series.  
 Standard treatment regimes include corticosteroids in addition to immunosuppressives. 
The role of corticosteroids in ASS associated ILD and their potential impact on disease 
course and patient survival is, however, unclear. Corticosteroids have little prospective 
evidence supporting their use (19), but their well documented intense anti-inflammatory 
efficacy suggests that they may be an essential part of initial therapeutic regimen. Moreover, 
the efficacy of corticosteroids in suppressing myositis is well documented. Thus, most 
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clinicians regard corticosteroids as a basic part of the therapeutic regimen of ASS. In acute or 
subacute pulmonary disease, high doses of oral glucocorticosteroids are usually 
administered (1 mg/kg/day). At some centers, intravenous methylprednisolon in doses of 
500-1000 mg/day for 2-3 consecutive days are used as initial treatment. It should be noted, 
however, that there are no studies that clearly show the superiority of intravenous to oral 
corticosteroid treatment. In gradually developing ILD (type II) moderate doses of 
corticosteroids (0.5 mg/day initially) are most often preferred. 
There is unfortunately no general consensus to what immunosuppressives that should be 
preferred in addition to corticosteroids in ASS. Although placebo-controlled trials are 
lacking, favorable experiences with cyclophosphamide in other connective tissue diseases 
have led many clinicians to prefer this drug as an adjunct to steroids. The choice of 
immunosuppressive treatment, however, clearly depends on the severity and extent of 
disease. In moderate to mild cases, a combination of oral glucocorticosteroids and either 
cyclophosphamide, azathioprine or methotrexate may be recommended. However, in our 
experience this regimen is insufficient in cases with acute and rapidly progressing ILD. 
Although based on retrospective case series, we recommend a combination of oral 
corticosteroids, cyclophosphamide and the anti-CD-20 monoclonal antibody rituximab as 
induction therapy in type I ASS (57). The efficacy of rituximab has also been reported in 
several case reports (58;59).  
Others have experienced favorable effect of calcineurin inhibitors such as cyclosporin A (60) 
and tacrolimus (23). Another therapeutic option is mycophenolate mofetil and for myositis 
methotrexate may be valuable as an adjunct to corticosteroids. Clearly, multicenter 
randomised controlled studies of the efficacy of immunosuppressive therapy in ASS is 
highly warranted. 
In end stage pulmonary disease, lung transplantation appears the only therapeutic option, 
but is rarely accepted due to oesophageal dysmotility. The dermatological manifestations 
may be favorable treated by hydroxychloroquine. 
13. Disease outcome 
The final outcome of ASS largely depends on the type and progression of ILD. Myositis 
have usually limited impact on outcome. The majority of patients run a chronic disease 
course (24) and will require immunosuppressive therapy for several years. Unfortunately, 
no follow-up study including a large number of patients have been performed to display the 
impact of ASS on functional outcome and quality of life. In one study of 12 patients followed 
for 5.5 years, muscle function improved in all and pulmonary function normalized in 1/3 
(32). 
In a study of 32 patients (61), patients with acute onset and respiratory insufficiency were 
compared to those with a gradual onset of ILD. The percentage of patients in whom the ILD 
improved at three months was significantly higher among those with acute onset. However, 
most patients with ILD progression after 12 months were among those with acute onset. 
Other studies have also shown an association between acute and subacute onset and poor 
prognosis (62). 
Whether or not the pattern of HRCT findings is indicative of final outcome is a matter of 
debate. Ground glass opacities, initially thought to represent reversible inflammation have 
been associated with a better response to therapy (63), hence a more favorable outcome. 
However, ground glass opacities may also represent fine reticular fibrosis, and some studies 
have suggested a poor prognosis in patients demonstrating such changes (64). Finally, 
mortality appears to have little relationship to biopsy subtype (19). 
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Mortality and causes of death in ASS have been rarely subjected to investigation. After an 
average of 5.5 years, only one of 12 patients succumed ((32) and mortality was estimated to 
8%. Others have found a cumulative mortality of 14% (9). At present, the overal annual 
mortality of ASS cannot be exactly assessed, but it can be concluded that ASS is associated 
with excess mortality. 
In general, the mortality in IIM has improved during the last decades, from a 5-year survival 
of 65% in the 1960ies compared to 75-96% in the last decade (65). If modern therapy and 
more aggressive therapy have had the same impact on ASS remains to be seen. 
14. Future perspectives  
ASS represent a rather newly defined disease entity whose etiopathogenesis remains 
incompletely understood. The disease course is usually chronic and ASS is most likely 
associated with decreased survival. Due to its low incidence large scale prospective 
investigations are few. Knowledge about the clinical aspects of ASS has accumulated, while 
outcome, prognostic markers, biomarkers for disease activity, treatment, mortality and risk 
of cancer have been insufficiently investigated.   
 
Anti-Jo-1 histidyl 
Anti-PL-12 alanyl 
Anti-PL-7 threonyl 
Anti-EJ glycyl 
Anti-OJ isoleucyl 
Anti-KS asparaginyl 
Anti-Zo phenylalanyl 
Anti-Ha tyrosyl 
Table 1. Antisynthetase autoantibodies. 
 
Antisynthetase autoantibody 
demonstrated on two separate occasions 
Plus at least one of the following 
Plus Arthritis/arthralgia 
Either Interstitial lung disease Raynaud`s phenomenon 
And/or Inflammatory muscle disease Gottron`s paples or sign 
 Mechanic`s hands 
 D 
Table 2. Suggested classification criteria for ASS. 
15. Reference  
[1] Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK et al. 
Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA 
synthetase enzymes. Q J Med 1990; 77(282):1019-38. 
[2] Hengstman GJ, Brouwer R, Egberts WT, Seelig HP, Jongen PJ, van Venrooij WJ et al. 
Clinical and serological characteristics of 125 Dutch myositis patients. Myositis 
specific autoantibodies aid in the differential diagnosis of the idiopathic 
inflammatory myopathies. J Neurol 2002; 249(1):69-75. 
www.intechopen.com
 
The Antisynthetase Syndrome 
 
73 
[3] Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T et al. 
Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese 
patients with dermatomyositis. J Rheumatol 2007; 34(5):1012-8. 
[4] O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M et al. 
Immunogenetic risk and protective factors for the idiopathic inflammatory 
myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles 
distinguish European American patients with different myositis autoantibodies. 
Medicine (Baltimore) 2006; 85(2):111-27. 
[5] Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a 
model for autoimmunity. Nature 1983; 304(5922):177-9. 
[6] Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and 
dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 
1980; 23(8):881-8. 
[7] Chinoy H, Salway F, Fertig N, Shephard N, Tait BD, Thomson W et al. In adult onset 
myositis, the presence of interstitial lung disease and myositis specific/associated 
antibodies are governed by HLA class II haplotype, rather than by myositis 
subtype. Arthritis Res Ther 2006; 8(1):R13. 
[8] Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of 
autoantibodies in 100 patients with autoimmune myositis: insights into clinical 
features and outcomes. Arthritis Res Ther 2007; 9(4):R78. 
[9] Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, 
Martinez-Gomez X, Vilardell-Tarres M. Myositis-specific and myositis-associated 
antibodies in a series of eighty-eight Mediterranean patients with idiopathic 
inflammatory myopathy. Arthritis Rheum 2006; 55(5):791-8. 
[10] Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic 
inflammatory myopathy: an update on clinical and pathophysiological significance. 
Curr Opin Rheumatol 2007; 19(6):523-9. 
[11] Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, van Venrooij WJ. 
Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from 
patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997; 
109(1):32-40. 
[12] Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M et al. Anti-Jo-1 antibody 
levels correlate with disease activity in idiopathic inflammatory myopathy. 
Arthritis Rheum 2007; 56(9):3125-31. 
[13] Vancsa A, Csipo I, Nemeth J, Devenyi K, Gergely L, Danko K. Characteristics of 
interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy 
patients. Rheumatol Int 2009; 29(9):989-94. 
[14] Mielnik P, Wiesik-Szewczyk E, Olesinska M, Chwalinska-Sadowska H, Zabek J. 
Clinical features and prognosis of patients with idiopathic inflammatory 
myopathies and anti-Jo-1 antibodies. Autoimmunity 2006; 39(3):243-7. 
[15] Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D et al. Anti-aminoacyl-
tRNA synthetase antibodies in clinical course prediction of interstitial lung disease 
complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 
39(3):233-41. 
[16] Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR et al. 
Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-
positive interstitial lung disease. Arthritis Rheum 2009; 60(7):2183-92. 
www.intechopen.com
 
Idiopathic Inflammatory Myopathies – Recent Developments 
 
74
[17] Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB et al. Myositis autoantibodies 
in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody 
is primarily associated with rapidly progressive interstitial lung disease 
independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 
2010; 11:223. 
[18] Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory 
myopathies: progress and pitfalls. Curr Opin Rheumatol 2010; 22(6):633-8. 
[19] Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease 
associated with the idiopathic inflammatory myopathies: what progress has been 
made in the past 35 years? Chest 2010; 138(6):1464-74. 
[20] Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M et al. Clinical 
manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA 
synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology 
(Oxford) 2010; 49(5):972-6. 
[21] Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium 
and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000; 68(4):472-8. 
[22] Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G et al. Interstitial lung 
disease in polymyositis and dermatomyositis: longitudinal evaluation by 
pulmonary function and radiology. Arthritis Rheum 2008; 59(5):677-85. 
[23] Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-
associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 
52(8):2439-46. 
[24] Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M et al. 
Clinical and pathological findings of interstitial lung disease patients with anti-
aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010; 49(5):361-9. 
[25] Yousem SA, Gibson K, Kaminski N, Oddis CV, Ascherman DP. The pulmonary 
histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Mod 
Pathol 2010; 23(6):874-80. 
[26] Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: 
a model for autoimmunity. Nature 1983; 304(5922):177-9. 
[27] Suber TL, Casciola-Rosen L, Rosen A. Mechanisms of disease: autoantigens as clues to 
the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008; 4(4):201-9. 
[28] Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M et al. Novel conformation of 
histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-
associated myositis. Arthritis Rheum 2007; 56(8):2729-39. 
[29] Ascherman DP, Oriss TB, Oddis CV, Wright TM. Critical requirement for professional 
APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase 
(Jo-1) in Jo-1 antibody-positive polymyositis. J Immunol 2002; 169(12):7127-34. 
[30] Englund P, Wahlstrom J, Fathi M, Rasmussen E, Grunewald J, Tornling G et al. 
Restricted T cell receptor BV gene usage in the lungs and muscles of patients with 
idiopathic inflammatory myopathies. Arthritis Rheum 2007; 56(1):372-83. 
[31] Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, 
Targoff IN, Blaszczyk-Kostanecka M et al. Clinical, serologic, and immunogenetic 
features in Polish patients with idiopathic inflammatory myopathies. Arthritis 
Rheum 1997; 40(7):1257-66. 
[32] Spath M, Schroder M, Schlotter-Weigel B, Walter MC, Hautmann H, Leinsinger G et al. 
The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 
2004; 251(7):859-64. 
www.intechopen.com
 
The Antisynthetase Syndrome 
 
75 
[33] La CR, Lo Mo NA, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase 
syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe 
interstitial lung disease. Autoimmunity 2006; 39(3):249-53. 
[34] Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK et al. 
Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the 
literature. Chest 2009; 135(6):1550-6. 
[35] Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies 
against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. 
Semin Arthritis Rheum 1996; 26(1):459-67. 
[36] Mii S, Kobayashi R, Nakano T, Harada H, Okada M, Matsui Y et al. A histopathologic 
study of mechanic's hands associated with dermatomyositis: a report of five cases. 
Int J Dermatol 2009; 48(11):1177-82. 
[37] Meyer O, Charlanne H, Cherin P, Allanore Y, Coquerelle P, Grardel B et al. Subluxing 
arthropathy: an unusual manifestation of the antisynthetase syndrome. Ann 
Rheum Dis 2009; 68(1):152-3. 
[38] Mumm GE, McKown KM, Bell CL. Antisynthetase syndrome presenting as 
rheumatoid-like polyarthritis. J Clin Rheumatol 2010; 16(7):307-12. 
[39] Disdier P, Bolla G, Harle JR, Pache X, Weiller-Merli C, Marco MS et al. [Digital necrosis 
disclosing antisynthetase syndrome]. Ann Dermatol Venereol 1994; 121(6-7):493-5. 
[40] Chatterjee S, Farver C. Severe pulmonary hypertension in Anti-Jo-1 syndrome. 
Arthritis Care Res (Hoboken ) 2010; 62(3):425-9. 
[41] Taniguchi Y, Horino T, Kato T, Terada Y. Acute pulmonary arterial hypertension 
associated with anti-synthetase syndrome. Scand J Rheumatol 2010; 39(2):179-80. 
[42] Cavagna L, Prisco E, Montecucco C, Caporali R. Pulmonary arterial hypertension in 
antisynthetase syndrome: Comment on the article by Chatterjee and Farver. 
Arthritis Care Res (Hoboken ) 2011; 63(4):633-4. 
[43] Minai OA. Pulmonary hypertension in polymyositis-dermatomyositis: clinical and 
hemodynamic characteristics and response to vasoactive therapy. Lupus 2009; 
18(11):1006-10. 
[44] Queiro-Silva R, Banegil I, de Dios-Jimenez de Aberasturi JR, Belzunegui-Otano J, 
Gonzalez-Beneitez C, Figueroa-Pedrosa M. Periarticular calcinosis associated with 
anti-Jo-1 antibodies sine myositis. Expanding the clinical spectrum of the 
antisynthetase syndrome. J Rheumatol 2001; 28(6):1401-4. 
[45] Frost NA, Morand EF, Hall CL, Maddison PJ, Bhalla AK. Idiopathic polymyositis 
complicated by arthritis and mesangial proliferative glomerulonephritis: case 
report and review of the literature. Br J Rheumatol 1993; 32(10):929-31. 
[46] Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R et al. Unusually high 
frequency of autoantibodies to PL-7 associated with milder muscle disease in 
Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 
54(6):2004-9. 
[47] Sato S, Hirakata M, Kuwana M, Nakamura K, Suwa A, Inada S et al. Clinical 
characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) 
autoantibodies. Clin Exp Rheumatol 2005; 23(5):609-15. 
[48] Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-
OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford) 2007; 
46(5):842-5. 
www.intechopen.com
 
Idiopathic Inflammatory Myopathies – Recent Developments 
 
76
[49] Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E et al. Clinical and 
immunogenetic features of patients with autoantibodies to asparaginyl-transfer 
RNA synthetase. Arthritis Rheum 2007; 56(4):1295-303. 
[50] Mileti LM, Strek ME, Niewold TB, Curran JJ, Sweiss NJ. Clinical characteristics of 
patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol 
2009; 15(5):254-5. 
[51] Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of 
myositis autoantibody testing for predicting the risk of cancer-associated myositis. 
Ann Rheum Dis 2007; 66(10):1345-9. 
[52] Legault D, McDermott J, Crous-Tsanaclis AM, Boire G. Cancer-associated myositis in 
the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J 
Rheumatol 2008; 35(1):169-71. 
[53] Rozelle A, Trieu S, Chung L. Malignancy in the setting of the anti-synthetase 
syndrome. J Clin Rheumatol 2008; 14(5):285-8. 
[54] Azuma K, Yamada H, Ohkubo M, Yamasaki Y, Yamasaki M, Mizushima M et al. 
Incidence and predictive factors for malignancies in 136 Japanese patients with 
dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod 
Rheumatol 2011; 21(2):178-83. 
[55] Park CK, Kim TJ, Cho YN, Kim IS, Lee HJ, Lee KE et al. Development of antisynthetase 
syndrome in a patient with rheumatoid arthritis. Rheumatol Int 2011; 31(4):529-32. 
[56] Mercer LK, Moore TL, Chinoy H, Murray AK, Vail A, Cooper RG et al. Quantitative 
nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. 
Rheumatology (Oxford) 2010; 49(9):1699-705. 
[57] Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase 
syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48(8):968-71. 
[58] Ball EM, Savage EM, Pendleton A. Refractory anti-synthetase syndrome treated with 
rituximab. Rheumatology (Oxford) 2010; 49(5):1013. 
[59] Frikha F, Rigolet A, Behin A, Fautrel B, Herson S, Benveniste O. Efficacy of rituximab 
in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. 
Rheumatology (Oxford) 2009; 48(9):1166-8. 
[60] Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A et al. Early intervention 
with corticosteroids and cyclosporin A and 2-hour postdose blood concentration 
monitoring improves the prognosis of acute/subacute interstitial pneumonia in 
dermatomyositis. J Rheumatol 2008; 35(2):254-9. 
[61] Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D et al. 
Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and 
gradual onset. Thorax 2008; 63(1):53-9. 
[62] Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK et al. Interstitial lung disease 
in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. 
Rheumatology (Oxford) 2005; 44(10):1282-6. 
[63] Mino M, Noma S, Taguchi Y, Tomii K, Kohri Y, Oida K. Pulmonary involvement in 
polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J 
Roentgenol 1997; 169(1):83-7. 
[64] Won HJ, Soon KD, Keun LC, Yoo B, Bum SJ, Kitaichi M et al. Two distinct clinical types 
of interstitial lung disease associated with polymyositis-dermatomyositis. Respir 
Med 2007; 101(8):1761-9. 
[65] Lundberg IE, Forbess CJ. Mortality in idiopathic inflammatory myopathies. Clin Exp 
Rheumatol 2008; 26(5 Suppl 51):S109-S114. 
www.intechopen.com
Idiopathic Inflammatory Myopathies - Recent Developments
Edited by Prof. Jan Tore Gran
ISBN 978-953-307-694-2
Hard cover, 212 pages
Publisher InTech
Published online 15, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The term "myositis" covers a variety of disorders often designated "idiopathic inflammatory myopathies".
Although they are rather rare compared to other rheumatic diseases, they often cause severe disability and
not infrequently increased mortality. The additional involvement of important internal organs such as the heart
and lungs, is not uncommon. Thus, there is a great need for a better understanding of the etiopathogenesis of
myositis, which may lead to improved treatment and care for these patients. Major advances regarding
research and medical treatment have been made during recent years. Of particular importance is the
discovery of the Myositis specific autoantibodies, linking immunological and pathological profiles to distinct
clinical disease entities. A wide range of aspects of myopathies is covered in the book presented by highly
qualified authors, all internationally known for their expertice on inflammatory muscle diseases. The book
covers diagnostic, pathological, immunological and therapeutic aspects of myositis.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Jan Tore Gran and Øyvind Molberg (2011). The Antisynthetase Syndrome, Idiopathic Inflammatory
Myopathies - Recent Developments, Prof. Jan Tore Gran (Ed.), ISBN: 978-953-307-694-2, InTech, Available
from: http://www.intechopen.com/books/idiopathic-inflammatory-myopathies-recent-developments/the-
antisynthetase-syndrome
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
